Across TCGA pan-cancer cohorts, DYNC1LI2 mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of DYNC1LI2’s most consistent transcriptional readouts.
The strongest signal is observed in colon adenocarcinoma (COAD), where DYNC1LI2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types DYNC1LI2 is over-expressed in tumor, although a few such as COAD and LSCC show the opposite, repressed pattern.
COAD, LSCC, and CCRCC are the cancer types where DYNC1LI2 tumor–normal differential expression is most reproducible.